Immunogenicity and safety of anti‐SARS‐CoV‐2 BNT162b2 vaccine in psoriasis patients treated with biologic drugs-Reference-Cited by-同舟云学术

Immunogenicity and safety of anti‐SARS‐CoV‐2 BNT162b2 vaccine in psoriasis patients treated with biologic drugs

Published:2021-12-17 Issue: Volume: Page:
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:Acad Dermatol Venereol

Author:

Cristaudo A.¹^ORCID,Graceffa D.¹^ORCID,Pimpinelli F.²,Sperati F.³,Spoletini G.⁴,Bonifati C.¹,Pellini R.⁵,Lora V.¹,Pontone M.²,Di Bella O.⁶,Bracco D.⁶,Morrone A.⁷

Affiliation:

1. Department of Clinical Dermatology San Gallicano Dermatological Institute IRCCS Rome Italy

2. Microbiology and Virology Unit Dermatological Clinical and Research Department San Gallicano Dermatological Institute IRCCS Rome Italy

3. Biostatistics Unit San Gallicano Dermatological Institute IRCCS Rome Italy

4. General Surgery and Liver Transplantation Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy

5. Department Otolaryngology Head and Neck Surgery IRCCS Regina Elena National Cancer Institute Rome Italy

6. Medical Direction IRCCS Regina Elena National Cancer Institute Rome Italy

7. Scientific Direction San Gallicano Dermatological Institute IRCCS Rome Italy

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.17861

Reference10 articles.

1. Immunogenicity and safety of anti‐SARS‐CoV‐2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort;Geisen UM;Ann Rheum Dis,2021

2. Immunogenicity and safety of the BNT162b2 mRNA COVID‐19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study;Furer V;Ann Rheum Dis,2021

3. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS‐CoV‐2;Braun‐Moscovici Y;Ann Rheum Dis,2021

4. SARS‐CoV‐2 vaccination responses in untreated, conventionally treated and anticytokine‐treated patients with immune‐mediated inflammatory diseases;Simon D;Ann Rheum Dis,2021

5. American College of Rheumatology Guidance for COVID‐19 vaccination in patients with rheumatic and musculoskeletal diseases: version 2;Curtis JR;Arthritis Rheumatol,2021

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity, Effectiveness, and Safety of COVID-19 Vaccines among Patients with Immune-Mediated Dermatological Diseases: A Systematic Review and Meta-analysis;Acta Dermato-Venereologica;2024-05-02

2. Psoriasis and biological drugs at the time of SARS-CoV-2 infection: a mini review outlining risk of infection, seroprevalence, and safety and efficacy of the BNT162b2 vaccine;Frontiers in Immunology;2024-01-30

3. PsoBioVax: A multicentric Italian case–control study of the immunological response to anti‐SARS‐CoV‐2 vaccine among psoriatic patients under biological therapy;Journal of the European Academy of Dermatology and Venereology;2023-12-07

4. Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis;Psoriasis: Targets and Therapy;2023-04

5. SARS‐CoV‐2 vaccination status and adverse events among patients with psoriasis—Data from the German Registries PsoBest and CoronaBest;Journal of the European Academy of Dermatology and Venereology;2023-03-27